Table 1.
Additional clinical characteristics and demographic profiles of patients
| Patient Characteristics | Value (N = 867) |
|---|---|
| Patient age | |
| median (range), y | 75 (51–96) |
| Sex, No. (%) | |
| Male | 565 (65) |
| Female | 302 (35) |
| Race, No. (%) | |
| Caucasian | 801 (92) |
| African American | 18 (2) |
| Hispanic | 25 (3) |
| Other | 19 (2) |
| AML classification, No. (%) | |
| De novo AML | 383 (44) |
| Secondary AML | 483 (56) |
| AML risk stratification, No. (%) | |
| Favorable-risk group | 21 (2) |
| Intermediate-risk group | 485 (56) |
| Poor-risk group | 266 (31) |
| History of prior or concurrent cancer, No. (%) | |
| Hematologic malignancies | 34 (4) |
| Solid tumors | 207 (24) |
| Prior thrombosis (arterial/venous) | 126 (14) |
| Growth factors, No. (%) | |
| Before AML diagnosis | 167 (19) |
| EPO | 101 (12) |
| G-CSF | 58 (7) |
| GM-CSF | 8 (1) |
| Post AML diagnosis | 728 (84) |
| Complete blood counts at diagnosis, No. (range) | |
| WBC (× 109/L) | 3.165 (0.08–413.74) |
| Hemoglobin (g/dL) | 9.3 (5.6–15.2) |
| Platelet (× 109/L) | 46 (1–800) |
| Treatment regimen, No. (%) | |
| Chemotherapy | 250 (29) |
| Hypomethylating agent | 240 (28) |
| Best supportive care | 225 (26) |
| BMI, No. (%) | |
| ≤ 35 kg/m2 | 820 (65) |
| > 35 kg/m2 | 47 (5) |
Abbreviations: AML acute myeloid leukemia, BMI body mass index, EPO erythropoietin, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte-macrophage colony-stimulating factor, WBC white blood cells